Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Larcher

Showing results (11-20 of 334) with videos related to

Pageof 34
Sort By:
European Urology Oncology|April 25, 2019
Re: Ricardo G. Alvim, François Audenet, Emily A. Vertosick, Daniel D. Sjoberg, Karim A. Touijer. Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and PADUA Systems. Eur Urol Oncol 2018;1:428-34: Nephrometry Score: Quantifying the Complexity of the Tumor or Struggling with the Complexity of the Score?Fabio Muttin, Umberto Capitanio, Francesco Montorsi, et al.
European Urology Open Science|January 6, 2022
Cytoreductive Nephrectomy in 2021: Obsolete but NecessaryUmberto Capitanio, Andrea Necchi, Francesco Montorsi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
The Authors RespondNicola Fossati, Alessandro Larcher, Alberto Briganti, et al.
European Urology|March 30, 2016
Oncologic Surveillance for Renal Cell Carcinoma: What Is Still Needed?Umberto Capitanio, Giorgio Gandaglia, Alessandro Larcher, et al.
The Journal of Urology|May 13, 2026
Interpreting Matched Analyses of Partial Versus Radical Nephrectomy for cT2 Tumors: Methodological Caveats and Clinical ImplicationsUmberto Capitanio, Francesco Cei, Alessandro Larcher, et al.
Urologic Oncology|June 1, 2022
Reply to Sebastiano Buti and Giulia Claire Giudice's Letter to the Editor comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: Is AUC close enough to clinical practice? Urol Oncol. 2022 Apr 14:S1078-1439(22)00066-7. doi: 10.1016/j.urolonc.2022.02.015Giuseppe Rosiello, Alessandro Larcher, Francesco Montorsi, et al.
European Urology|February 10, 2018
You Can Trust a Crystal Ball About as Far as You Can Throw ItUmberto Capitanio, Alessandro Larcher, Francesco Montorsi, et al.
European Urology|October 4, 2016
Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol Lancet 2016;17:1317-24: Active Surveillance in Metastatic Renal Cell Carcinoma: Option or Exception?Umberto Capitanio, Alessandro Larcher, Paolo Dell'Oglio, et al.
European Urology|October 15, 2022
Long-distance Robot-assisted Teleoperation: Every Millisecond CountsAlessandro Larcher, Federico Belladelli, Umberto Capitanio, et al.
European Urology|March 14, 2022
Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022;81:576-85Francesco Montorsi, Umberto Capitanio, Giuseppe Rosiello, et al.
Pageof 34

Showing results (11-20 of 334) with videos related to

Sort By:
Pageof 34
European Urology Oncology|April 25, 2019
Re: Ricardo G. Alvim, François Audenet, Emily A. Vertosick, Daniel D. Sjoberg, Karim A. Touijer. Performance Prediction for Surgical Outcomes in Partial Nephrectomy Using Nephrometry Scores: A Comparison of Arterial Based Complexity (ABC), RENAL, and PADUA Systems. Eur Urol Oncol 2018;1:428-34: Nephrometry Score: Quantifying the Complexity of the Tumor or Struggling with the Complexity of the Score?Fabio Muttin, Umberto Capitanio, Francesco Montorsi, et al.
European Urology Open Science|January 6, 2022
Cytoreductive Nephrectomy in 2021: Obsolete but NecessaryUmberto Capitanio, Andrea Necchi, Francesco Montorsi, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
The Authors RespondNicola Fossati, Alessandro Larcher, Alberto Briganti, et al.
European Urology|March 30, 2016
Oncologic Surveillance for Renal Cell Carcinoma: What Is Still Needed?Umberto Capitanio, Giorgio Gandaglia, Alessandro Larcher, et al.
The Journal of Urology|May 13, 2026
Interpreting Matched Analyses of Partial Versus Radical Nephrectomy for cT2 Tumors: Methodological Caveats and Clinical ImplicationsUmberto Capitanio, Francesco Cei, Alessandro Larcher, et al.
Urologic Oncology|June 1, 2022
Reply to Sebastiano Buti and Giulia Claire Giudice's Letter to the Editor comparing the prognostic models to predict oncologic outcomes in patients with renal cell carcinoma: Is AUC close enough to clinical practice? Urol Oncol. 2022 Apr 14:S1078-1439(22)00066-7. doi: 10.1016/j.urolonc.2022.02.015Giuseppe Rosiello, Alessandro Larcher, Francesco Montorsi, et al.
European Urology|February 10, 2018
You Can Trust a Crystal Ball About as Far as You Can Throw ItUmberto Capitanio, Alessandro Larcher, Francesco Montorsi, et al.
European Urology|October 4, 2016
Re: Brian I. Rini, Tanya B. Dorff, Paul Elson, et al. Active Surveillance in Metastatic Renal-cell Carcinoma: A Prospective, Phase 2 Trial. Lancet Oncol Lancet 2016;17:1317-24: Active Surveillance in Metastatic Renal Cell Carcinoma: Option or Exception?Umberto Capitanio, Alessandro Larcher, Paolo Dell'Oglio, et al.
European Urology|October 15, 2022
Long-distance Robot-assisted Teleoperation: Every Millisecond CountsAlessandro Larcher, Federico Belladelli, Umberto Capitanio, et al.
European Urology|March 14, 2022
Re: Sarah P. Psutka, Roman Gulati, Michael A.S. Jewett, et al. A Clinical Decision Aid to Support Personalized Treatment Selection for Patients with Clinical T1 Renal Masses: Results from a Multi-institutional Competing-risks Analysis. Eur Urol. 2022;81:576-85Francesco Montorsi, Umberto Capitanio, Giuseppe Rosiello, et al.
Pageof 34